E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Antiretroviral experienced, HIV-1 Infection.
Adequate ICD classification code not available. |
|
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 8.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10020192 |
E.1.2 | Term | HIV-1 |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
The primary objectives of this study are to compare the safety, tolerability and antiviral activity of QD and BID dosing of the lopinavir/ritonavir tablet formulation in subjects with detectable viral load while receiving their current antiretroviral therapy.
|
|
E.2.2 | Secondary objectives of the trial |
The secondary objective of this study is to characterize the development of resistance in QD and BID dosing of the lopinavir/ritonavir tablet in antiretroviral-experienced subjects.
|
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
A subject will be eligible for study participation if he/she meets the following criteria: 1. Subject is at least 18 years of age. 2. Subject has voluntarily signed and dated an informed consent form, approved by an Institutional Review Board (IRB)/Independent Ethics Committee (IEC), after the nature of the study has been explained and the subject has had the opportunity to ask questions. The informed consent must be signed before any study-specific procedures are performed. 3. Subject agrees not to take any medication during the study, including over the counter medicines, vitamins, minerals, herbal preparations, alcohol or recreational drugs without the knowledge of the principal investigator. 4. Subject does not require and agrees not to take any drugs that are contraindicated with study drugs during the course of the study. For complete information, refer to the most current product label for locally approved prescribing information for lopinavir/ritonavir (Kaletra®) and other investigator-selected coadministered antiretroviral agents. 5. Subject has not been treated for an active AIDS-defining opportunistic infection within 30 days of initiating study drug (as denoted by * in Appendix D). Subjects who are on stable maintenance therapy for an opportunistic infection may be enrolled after consultation with the Abbott Medical Monitor. 6. Subject's vital signs, physical examination and laboratory results do not exhibit evidence of acute illness. 7. If female, subject must be either postmenopausal for at least one year, surgically sterile (bilateral tubal ligation, bilateral oorphorectomy or hysterectomy), or she must: · use a non-hormonal method of birth control that is acceptable to both the subject and investigator, and is consistent with the locally approved prescribing information for lopinavir/ritonavir; and · have a urine pregnancy test performed at the Screening Visit and on Day 1/Baseline, and results of both tests must be negative. 8. Subject is not breast-feeding. 9. Subject is currently receiving an antiretroviral regimen which has not changed for at least 12 weeks. 10. Subject has never received lopinavir/ritonavir. 11. Subject is currently failing his/her antiretroviral regimen with the most recent two consecutive pre-study plasma HIV-1 RNA levels > 400 copies/mL with the most recent being > 1000 copies/mL, and in the investigator's opinion, should change therapy. 12. Subject has plasma HIV-1 RNA levels > 1000 copies/mL at Screening. 13. Based on HIV-1 drug resistance genotypic test results at the Screening Visit and prior treatment history, the investigator considers lopinavir/ritonavir plus at least two NRTIs to be an appropriate treatment for the subject. 14. Subject does not require and agrees not to take any antiretroviral medication except lopinavir/ritonavir and NRTIs.
|
|
E.4 | Principal exclusion criteria |
A subject will be excluded from the study if he/she meets any of the following criteria: 1. Subject has a history of an allergic reaction or significant sensitivity to lopinavir or ritonavir. 2. Subject has an ongoing history of substance abuse (recreational drugs, alcohol) or psychiatric illness that could preclude adherence with the protocol. 3. Subject has significant history of cardiac, renal, neurologic, psychiatric, oncologic, metabolic or hepatic disease that would adversely affect his/her participating in this study. 4. Subject has received any investigational drug or investigational vaccine within 30 days prior to study drug administration. 5. For any reason, subject is considered by the investigator to be an unsuitable candidate for the study. 6. Screening laboratory analyses show any of the following abnormal laboratory results: ● Hemoglobin less than or equal to 8.0 g/dL ● Absolute neutrophil count less than or equal to 750 cells/mcL ● Platelet count less than or equal to 50,000 mm3 ● ALT (SGOT) or AST (SGPT) greater than or equal to 5.0 x Upper Limit of Normal (ULN)
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
The primary efficacy variable will be the proportion of subjects responding (i.e., not demonstrating virologic failure) at Week 48. |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | Information not present in EudraCT |
E.7.1.2 | Bioequivalence study | Information not present in EudraCT |
E.7.1.3 | Other | Information not present in EudraCT |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | Yes |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 6 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 80 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | Information not present in EudraCT |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
|
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 1 |
E.8.9.1 | In the Member State concerned months | 9 |
E.8.9.1 | In the Member State concerned days | |
E.8.9.2 | In all countries concerned by the trial years | 1 |
E.8.9.2 | In all countries concerned by the trial months | 9 |